Background
Ocular metastases of cutaneous melanoma exclusive to the vitreous are a rare presentation and usually represent disseminated disease. Although traditionally associated with poor outcomes, recent developments in melanoma treatment have vastly improved prognosis.

Aims
To review new targeted therapies for metastatic-melanoma.

Methods
Literature review of current clinical guidelines, systematic reviews and case series surrounding current recommended targeted therapies for metastatic-melanoma.

Results
New targeted therapeutic agents offer improved treatment response, progression free survival, overall survival and have a better side-effect profile than traditional chemotherapy agents for metastatic melanoma.

Conclusion
Targeted agents for melanoma have improved patient prognosis and life expectancy, likely leading to reduced need for surgical intervention.